• John Fanikos, Allison E Burnett, Charles E Mahan, and Paul P Dobesh.
• Department of Pharmacy, Brigham and Women's Hospital, Boston, Mass. Electronic address: jfanikos@partners.org.
• Am. J. Med. 2017 Oct 1; 130 (10): 1137-1143.

AbstractBecause differences in renal function can affect the efficacy and safety of direct oral anticoagulants, prescribing an appropriate dose based on renal function is critical, especially in patient populations with a high incidence of renal impairment. In patients with nonvalvular atrial fibrillation and mild or moderate renal impairment, direct oral anticoagulants are associated with a better risk-benefit profile compared with warfarin. However, less is known regarding outcomes in patients with venous thromboembolism and renal impairment. The efficacy and safety of direct oral anticoagulants in patients with venous thromboembolism and renal impairment are primarily derived from prespecified subgroup analyses of the phase 3 clinical trials. We summarize the available data on direct oral anticoagulant use in patients with venous thromboembolism and renal impairment. Clinicians are encouraged to follow study inclusion/exclusion criteria and perform renal dose adjustments based on the Cockcroft-Gault equation using actual body weight when indicated to avoid adverse events.Copyright © 2017 Elsevier Inc. All rights reserved.

14 keywords...

hide…